Email Alert | RSS    帮助

中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (6): 619-624.doi: 10.3969/j.issn.1000-6621.2021.06.017

• 综述 • 上一篇    下一篇


廖伟明*, 付亮, 邓国防, 袁小亮()   

  1. 南方科技大学附属深圳市第三人民医院肺二科(付亮、邓国防)/赣南医学院第一附属医院呼吸内科(袁小亮)
  • 收稿日期:2021-01-19 出版日期:2021-06-10 发布日期:2021-06-02
  • 通信作者: 袁小亮
  • 基金资助:

Research progress of bedaquiline for the treatment of multidrug-resistant tuberculosis

LIAO Wei-ming*, FU Liang, DENG Guo-fang, YUAN Xiao-liang()   

  1. *The First Clinical Medical College of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China
  • Received:2021-01-19 Online:2021-06-10 Published:2021-06-02
  • Contact: YUAN Xiao-liang



关键词: 结核,抗多种药物性, 贝达喹啉, 临床方案, 研究


The emergence and spread of multidrug-resistant tuberculosis (MDR-TB) has become a major obstacle to the World Health Organization’s End TB Strategy by 2035. Some studies have shown that the treatment success rate of MDR-TB with second-line anti-TB drugs was lower, and it was even worse in the patients with extensive drug-resistant tuberculosis (XDR-TB). Therefore, there is an urgent need to develop new anti-tuberculosis drugs. Bedaquiline is the first drug approved for the treatment of MDR-TB in the past 50 years. It can significantly increase the cure rate of MDR-TB and shorten the treatment duration. In order to improve the clinical doctors’ understanding of bedaquiline on MDR-TB treatment, we wrote this paper by reviewing the status of bedaquiline in the treatment of MDR/XDR-TB, the clinical research progress and several relevant issues.

Key words: Tuberculosis,multidrug-resistant, Bedaquline, Clinical protocols, Research